|18th November 2019
In the past year, the competition in biosimilars and complex generics has complicated the launch landscape. An abundance of discoveries coupled with radically evolving stakeholder needs is also straining the traditional pharmaceutical launch.
In this special pack, we provide a comprehensive outlook of launch excellence. We cover topics ranging from gathering effective insights, to understanding the current landscape, and the importance of pre-launch strategy for improving relationships between the customer and the brand.
The report also features interviews with key players such as organisational transformation expert Philip Atkinson. He shares his unique perspective on the importance of structuring agile organisational change to help pharmaceutical companies adapt and stay competitive.
These articles are complemented by case studies curated by our experienced in-house team.
In this publication, we help you answer the following questions:
Are you prepared for a successful launch?
How can you use insights to understand customers decision-making behaviour?
What are you missing in your CAR-T service launch?
How do you stay competitive with a lean pharmaceutical launch?
Multi-indication launches - how do you navigate in this space?
|20th May 2020
Healthcare companies increasingly claim to be “patient-centric” and create functions that are responsible for patient advocacy and engagement, but are they one and the same? Can you undertake patient engagement without being patient-centric, and vice-versa? Why should pharma engage with patients at all? And who should they be engaging with? Trishna Bharadia, a “pro patient” consultant, delves into the ins and outs of pharma industry collaboration with patients.
|11th May 2020
In the first of this three-part series, we speak to Kate Baker, a single mum who battled brain tumour and has now signed up to be a healthcare volunteer during the COVID-19 pandemic.
|22nd April 2020
MS patient Trishna Bharadia reveals what her life has been like during the COVID-19 pandemic, and how the healthcare industry can help improve outcomes for ‘at risk’ patients during this time.